news_6

ENHERTU® Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2 Low Metastatic Breast Cancer

First HER2 low metastatic breast cancer phase 3 results for Daiichi Sankyo and AstraZeneca’s ENHERTU offer potential to redefine how...